{"id":"W4412974237","doi":"10.1158/2767-9764.crc-25-0019","title":"Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; University of Alberta; Spinal Cord Injury BC; Ontario Institute for Cancer Research; Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Merck Canada; National Cancer Institute; Incyte; Memorial Sloan-Kettering Cancer Center; BeiGene; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00315335,0.0009127446,0.0008870105,0.0001953218,0.0003193865,0.0004685433,0.0004435748,0.000872681,0.003675829],"category_scores_gemma":[0.001651894,0.0003790241,0.0007677872,0.0001846308,0.0004941424,0.0005790808,0.000263005,0.001519459,0.0006360812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005201009,"about_ca_system_score_gemma":0.001440089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005166878,"about_ca_topic_score_gemma":0.001481693,"domain_scores_codex":[0.9991272,0.0005497854,0.00004215391,0.0001106178,0.00008266718,0.00008762384],"domain_scores_gemma":[0.9990337,0.0002160396,0.0002738721,0.00007723172,0.0001150583,0.0002840827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8069577,0.05122985,0.02228033,0.0009690849,0.001483435,0.0001807352,0.0003882028,0.0007665917,0.04991868,0.0002489433,0.002328066,0.06324837],"study_design_scores_gemma":[0.4714347,0.4957244,0.02365408,0.00004490993,0.0005032258,0.0002038334,0.00007087229,0.0007363044,0.004237337,0.0002149539,0.003157451,0.00001798618],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917304,0.0009569377,0.0007053057,0.0002297836,0.00006895072,0.004751284,0.0007115693,0.00005061399,0.0007951934],"genre_scores_gemma":[0.9910124,0.0004805341,0.001564355,0.0004099751,0.0000785013,0.004596685,0.0005944744,0.0000148432,0.001248284],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003675829,"threshold_uncertainty_score":0.01667672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3892141963931314,"score_gpt":0.6154104701398585,"score_spread":0.2261962737467271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}